You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永太科技(002326.SZ):全資子公司獲得磷酸西格列汀片、鹽酸莫西沙星片的藥品註冊證書
格隆匯 06-25 17:09

格隆匯6月25日丨永太科技(002326.SZ)公佈,公司全資子公司浙江永太藥業有限公司於近日收到國家藥品監督管理局核准簽發的關於磷酸西格列汀片、鹽酸莫西沙星片的《藥品註冊證書》。

磷酸西格列汀是由默沙東公司研製開發的一種二肽基肽酶-4(DPP-4)抑制劑,於2006年10月首次在美國批准,用於改善2型糖尿病患者的血糖控制。

鹽酸莫西沙星片屬於第四代喹諾酮類抗菌藥,與前三代藥物相比,其不良反應更小,對部分感染,如呼吸道感染的主要病原菌肺炎鏈球菌、流感嗜血桿菌、卡他莫拉菌及肺炎克雷伯菌等顯示出更強的抗菌活性;同時具有抗菌譜廣,耐藥性低,半衰期長等優勢。鹽酸莫西沙星片主要用於治療成人(≥18歲)敏感細菌所引起的感染,包括急性細菌性鼻竇炎、慢性支氣管炎急性發作、社區獲得性肺炎、非複雜性皮膚和皮膚組織感染、複雜性皮膚和皮膚組織感染、複雜性腹腔內感染等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account